Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) Interest Expenses (2020 - 2023)

Historic Interest Expenses for Dr Reddys Laboratories (RDY) over the last 6 years, with Q1 2017 value amounting to $12.0 million.

  • Dr Reddys Laboratories' Interest Expenses rose 37528.33% to $12.0 million in Q1 2017 from the same period last year, while for Dec 2017 it was $12.0 million, marking a year-over-year increase of 3234.35%. This contributed to the annual value of $33.0 million for FY2025, which is 5714.29% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Interest Expenses stood at $12.0 million for Q1 2017, which was up 37528.33% from $2.4 million recorded in Q4 2016.
  • In the past 5 years, Dr Reddys Laboratories' Interest Expenses registered a high of $12.0 million during Q1 2017, and its lowest value of -$2.2 million during Q4 2014.
  • For the 4-year period, Dr Reddys Laboratories' Interest Expenses averaged around $2.1 million, with its median value being $2.0 million (2016).
  • The largest annual percentage gain for Dr Reddys Laboratories' Interest Expenses in the last 5 years was 123670.47% (2015), contrasted with its biggest fall of 23953.03% (2015).
  • Quarter analysis of 4 years shows Dr Reddys Laboratories' Interest Expenses stood at -$2.2 million in 2014, then soared by 211.34% to $2.4 million in 2015, then grew by 0.22% to $2.4 million in 2016, then soared by 392.09% to $12.0 million in 2017.
  • Its Interest Expenses stands at $12.0 million for Q1 2017, versus $2.4 million for Q4 2016 and $1.9 million for Q3 2016.